STRUCTURAL BIOLOGY SHARED RESOURCE (Core-405) ABSTRACT Overview: The Structural Biology Shared Resource (SBSR) aims to facilitate and promote the application of macromolecular structural biology methods in cancer research for UCCC members. SBSR meets these goals by providing UCCC members instrumentation and expertise in X-ray Crystallography (X-ray) and Nuclear Magnetic Resonance Spectroscopy (NMR). Examples of projects studied in the SBSR fall into three main topic areas: Dynamics of cancer target activity, gene regulation, chromatin and epigenetics, and molecular targeting for the development of novel anti-tumor agents. Equipment: The SBSR capabilities have expanded significantly over the last 5 years through institutional support and the NIH Shared Instrument Grant Program. As a result, the X-ray facility has acquired a new in-house data-collection system that consists of a Rigaku MicroMax-007 X- ray generator, PILATUS3 R 200K Hybrid Pixel Array Detector with VariMax Optics and Oxford cryo-cooling systems. It also has a Rigaku/MSC robotics system for production of crystallization screens, drop setting and plate imaging. The NMR facility is equipped with Agilent/Varian 500, 600 and 900 MHz spectrometers at the Anschutz Medical Campus and an Agilent/Varian 800 MHz spectrometer at the UCB campus. Services: The SBSR provides expertise and access to highly specialized instrumentation for X-ray crystallography and NMR based structural studies of biomolecules relevant in cancer biology. Consultation and Education: SBSR personnel provide advice on sample preparation, data collection, structure determination, and data presentation for publication. Hands-on instrument training is important function of SBSR staff. Management: The SBSR is an institutional core managed by the institution as part of the Structural Biology and Biophysics Core Facilities. CCSG funding represents 34% of the annual operating budget. The remaining support comes from institutional support (50%) and user fees (16%). In regard to UCCC, SBSR is overseen by the Associate Director for Basic Research. Use of Services: Since July 2011, 54 investigators have used the services. Thirty-five percent of users were UCCC members, representing five of the six UCCC Research Programs and resulting in 55 peer- reviewed publications. Future Directions: The SBSR has several primary future directions that will enhance the SR and UCCC member cancer research: 1) Outreach to UCCC members from non-structure labs to create awareness of the opportunities SBSR technology offers and provide training in such technology; 2) incorporate into SBSR the new Cryo-Electron Microscopy resources that are currently being developed; 3) Collaborate with PMTSR to develop a comprehensive protein expression and purification service; 4) Initiate lifecycle replacement of several NMR resources.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA046934-30
Application #
9429056
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2018-02-01
Budget End
2019-01-31
Support Year
30
Fiscal Year
2018
Total Cost
Indirect Cost
Name
University of Colorado Denver
Department
Type
DUNS #
041096314
City
Aurora
State
CO
Country
United States
Zip Code
80045
New, Melissa L; White, Collin M; McGonigle, Polly et al. (2018) Prostacyclin and EMT Pathway Markers for Monitoring Response to Lung Cancer Chemoprevention. Cancer Prev Res (Phila) 11:643-654
Vartuli, Rebecca L; Zhou, Hengbo; Zhang, Lingdi et al. (2018) Eya3 promotes breast tumor-associated immune suppression via threonine phosphatase-mediated PD-L1 upregulation. J Clin Invest 128:2535-2550
Scott, Aaron J; Arcaroli, John J; Bagby, Stacey M et al. (2018) Cabozantinib Exhibits Potent Antitumor Activity in Colorectal Cancer Patient-Derived Tumor Xenograft Models via Autophagy and Signaling Mechanisms. Mol Cancer Ther 17:2112-2122
da Silva, Raquel Frenedoso; Dhar, Deepanshi; Raina, Komal et al. (2018) Nintedanib inhibits growth of human prostate carcinoma cells by modulating both cell cycle and angiogenesis regulators. Sci Rep 8:9540
Majtan, Tomas; Jones Jr, Wendell; Krijt, Jakub et al. (2018) Enzyme Replacement Therapy Ameliorates Multiple Symptoms of Murine Homocystinuria. Mol Ther 26:834-844
Dhar, Deepanshi; Deep, Gagan; Kumar, Sushil et al. (2018) Bitter melon juice exerts its efficacy against pancreatic cancer via targeting both bulk and cancer stem cells. Mol Carcinog 57:1166-1180
Donson, Andrew M; Amani, Vladimir; Warner, Elliot A et al. (2018) Identification of FDA-Approved Oncology Drugs with Selective Potency in High-Risk Childhood Ependymoma. Mol Cancer Ther 17:1984-1994
Branchford, B R; Stalker, T J; Law, L et al. (2018) The small-molecule MERTK inhibitor UNC2025 decreases platelet activation and prevents thrombosis. J Thromb Haemost 16:352-363
Pei, Shanshan; Minhajuddin, Mohammad; Adane, Biniam et al. (2018) AMPK/FIS1-Mediated Mitophagy Is Required for Self-Renewal of Human AML Stem Cells. Cell Stem Cell 23:86-100.e6
Ren, Shengxiang; Rivard, Christopher J; Yu, Hui et al. (2018) A miRNA Panel Predicts Sensitivity of FGFR Inhibitor in Lung Cancer Cell Lines. Clin Lung Cancer 19:450-456

Showing the most recent 10 out of 1634 publications